Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029965 | 1.00 | FDFT1 (0.49) | FDFT1MDM4TP53CASP3KMT2A | |
| SCHEMBL29362132 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL29087900 | 0.91 | FDFT1 (0.49) | FDFT1MDM4TP53CASP3KMT2A | |
| SCHEMBL29762010 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL800305 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL23056266 | 0.91 | FDFT1 (0.49) | FDFT1MDM4TP53CASP3HDAC1 | |
| SCHEMBL800035 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL4600701 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL29400804 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 | |
| SCHEMBL29768618 | 0.91 | FDFT1 (0.57) | FDFT1MDM4TP53CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816489-B2 | Methods for making intermediates and oxytocin analogues | FERRING B.V. (NL) | 2010-10-19 | — | — | US | disclosed |
| US-20080177035-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | FERRING B.V. (NL) | 2008-07-24 | — | — | US | disclosed |
| US-7304181-B2 | Methods for making intermediates and oxytocin analogues | FERRING BV (NL) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177035-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | OXTR, AVPR1A, AVPR1B | FDFT1 2321/4885MDM4 4391/4885TP53 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.